S&P 500 Research & Development Expense as a Share of Revenue (TTM)

Live value temporarily unavailable.

Source: Company filings (aggregated)

Data updated daily

What it measures

The S&P 500 R&D-to-revenue ratio measures aggregate research and development expense as a percentage of aggregate revenue for index constituents on a trailing-twelve-month basis. A reading of 3.0% means S&P 500 companies collectively spent $3 on R&D for every $100 of revenue, investing in future products, technologies, or competitive advantages.

Why it matters

R&D intensity is a forward-looking indicator of innovation investment and future revenue potential. At the index level, rising R&D-to-revenue reflects the increasing weight of technology, healthcare, and pharmaceutical companies that derive long-term value from intellectual property. Unlike capex, R&D is expensed immediately under GAAP, which means high R&D companies depress current earnings while building future value — making earnings-based valuation multiples structurally misleading for them without adjustment. Falling R&D ratios can signal either improved capital efficiency or cost-cutting that sacrifices future growth.

How it is calculated

R&D / Revenue (TTM) = Σ TTM R&D Expense ÷ Σ TTM Revenue × 100

LENSE computes the S&P 500 R&D-to-revenue ratio as aggregate TTM research and development expense divided by aggregate TTM revenue — not a simple average of per-company ratios. R&D expense per constituent is sourced from as-reported quarterly income statements; TTM figures are constructed by summing the four most recently reported quarters. Constituents that do not separately disclose R&D expense contribute zero to the numerator. Constituents with zero or negative revenue are excluded. Index constituency is resolved point-in-time using point-in-time index constituency.

Recent (monthly)

Recent data unavailable.

Data source: Company filings (aggregated). Computed and published by LENSE Analytics.